Consideration for Grant of Rights. (a) License Issue Fee and Patent Cost Reimbursement. COMPANY shall pay to M.I.T. on the EFFECTIVE DATE a license issue fee of [**] dollars ($[**]), and, in accordance with Section 6.3, shall reimburse M.I.T. for its actual expenses incurred as of the EFFECTIVE DATE in connection with obtaining the PATENT RIGHTS. These payments are nonrefundable.
Consideration for Grant of Rights. (a) License Issue Fee and Patent Cost Reimbursement. COMPANY shall pay to XXXXXXXXX within [***] days of the EFFECTIVE DATE a license issue fee of [***], and such amounts required as reimbursement in accordance with Section 6.3, relating to actual expenses incurred as of the EFFECTIVE DATE in connection with obtaining the PATENT RIGHTS. These payments are nonrefundable.
Consideration for Grant of Rights. (a) License Issue Fee and Patent Cost Reimbursement. COMPANY shall pay to M.I.T. within thirty (30) days of the EFFECTIVE DATE, a license issue fee of [***], and in accordance with Section 6.3, shall reimburse M.I.T for its actual expenses incurred as of the EFFECTIVE DATE in connection with obtaining the PATENT RIGHTS. These payments are nonrefundable.
Consideration for Grant of Rights. In consideration for the use of the DataTile Platform the Licensee shall pay the Licensor the non-refundable License Fees calculated based on the Tariff plan chosen by the Licensee.
Consideration for Grant of Rights. 4.1. License Fee, hi partial consideration of the rights granted Company under this Agreement, Company shall pay to Medical School within ten (10) days after the Effective Date a license fee of (***). The license fee is noncancelable (even if Company terminates pursuant to Section 8.3), nonrefundable and not creditable against any other payments due to Medical School under this Agreement.
Consideration for Grant of Rights. (a) License Issue Fee, Patent Cost Reimbursement,
Consideration for Grant of Rights. (a) License Issue Fee and Patent Cost Reimbursement. COMPANY shall pay to M.I.T. on the EFFECTIVE DATE a license issue fee of [***] dollars ($[***]), and, in accordance with Section 6.4, shall reimburse M.I.T. for its actual expenses incurred as of the EFFECTIVE DATE in connection with obtaining the PATENT RIGHTS. These payments are nonrefundable. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Consideration for Grant of Rights. In consideration for the rights, privileges and licenses granted herein, Company agrees to pay to NU in the manner hereinafter provided:
Consideration for Grant of Rights. In consideration of the rights granted by AnalytiCon to Pharvaris over the Term of this Agreement and the B2R Agreement, upon this License Agreement and the B2R Agreement becoming effective (whichever is later), a payment by Pharvaris of a onetime upfront license fee of [*****] shall become due (License and Research Execution Fee”) and shall be payable within 14 days from this License Agreement and the B2R Agreement becoming effective (whichever is later).
Consideration for Grant of Rights. (a) License Issue Fee and Patent Cost Reimbursement. COMPANY shall pay to M.I.T. within [***] business days following the EFFECTIVE DATE a license issue fee of [***]. In addition, in accordance with Section 6.3, COMPANY shall reimburse M.I.T. for its actual expenses incurred as of the EFFECTIVE DATE in connection with obtaining the PATENT RIGHTS. These payments are nonrefundable.
(b) Option Fee and Patent Cost Reimbursement. COMPANY shall reimburse M.I.T. within [***] business days following the EFFECTIVE DATE in the amount of [***] for its actual expenses incurred as of the EFFECTIVE DATE in connection with obtaining the patent rights set forth in Appendix C. In addition, within [***] days after M.I.T. invoices COMPANY, COMPANY shall reimburse M.I.T. for all reasonable patent-related expenses (including attorneys’ fees) incurred by M.I.T. during the OPTION PERIOD in connection with obtaining or maintaining the patent rights set forth in Appendix C.
